PHARMACEUTICAL COMPOSITION CONTAINING ANTITUMOR AGENT

WIPO Patent Application WO/2020/090970

A1

The purpose of the present invention is to provide a pharmaceutical composition which contains succinate of (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidine-5-yl)-4-pentyne-1-yl)amino)-1-oxopropane-2-yl)-4-(dimethylamino)-N-methyl-2-butenamide which elutes quickly in a weakly acidic test solution. With the present invention, a pharmaceutical composition which contains succinate of (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidine-5-yl)-4-pentyne-1-yl)amino)-1-oxopropane-2-yl)-4-(dimethylamino)-N-methyl-2-butenamide and at least one item selected from a group consisting of cellulose, sugars and sugar alcohols is provided.

JP2010539160	Pharmaceutical composition with antidiabetic activity
JP2002510336	[Title of the Invention] A pharmaceutical preparation containing a water-soluble ketoprofen salt and a method for using the same.
JP7062246	Vitamin D analog preparation and its preparation method

OURA TAI (JP)

PCT/JP2019/042750

May 07, 2020

October 31, 2019

Click for automatic bibliography generation  

FUJIFILM CORP (JP)

A61K9/48; A61K31/505; A61K47/12; A61K47/26; A61K47/38; A61P35/00; A61P35/02

WO2015056683A1	2015-04-23
WO2009101940A1	2009-08-20
WO2015056683A1	2015-04-23

YAMAURA TAKESHI ET AL.: "A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations", BLOOD, vol. 131, no. 4, 25 January 2018 (2018-01-25), pages 426 - 438, XP055704328
JAPANESE JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, vol. 34, no. 3, 2008, pages 289 - 296
JOURNAL OF JAPANESE SOCIETY OF GASTROENTEROLOGY, vol. 85, no. 7, 1988, pages 1353 - 1359
"Bioequivalence test of pharmaceutical products - Guideline compliance", 2013, pages: 35
See also references of EP 3875091A4

SIKs & Co. (JP)

View/Download PDF      PDF Help

Previous Patent: PACKAGE FOR MEDICAL COMPOSITION CONTAINING ANTI-TUMOR AGENT

Next Patent: TABLET CONTAINING ANTITUMOR AGENT